U.S. TTR revenue up 114% year over year, with a $21 million drag from inventory dynamics; international TTR growth of 7% quarter-over-quarter and 31% year-over-year.

Tafamidis generic entry delayed to mid-2031, extending AMVUTTRA’s competitive window in the U.S.

Rare disease net revenue reached $142 million, up 11% year over year from GIVLAARI and OXLUMO brands.

AMVUTTRA run rate surpasses $4 billion annually, about 15 months into the ATTR cardiomyopathy launch.

TTR net product revenues reach $1.03 billion in Q2 2026, up 89% year over year and the first quarter over $1 billion in TTR revenue.

Alnylam reports Q2 2026 total net product revenues around $1.2 billion, up 74% year over year, led by AMVUTTRA uptake in ATTR cardiomyopathy.

TRITON-CM enrollment expanded to 1,750 patients to mitigate low event-rate risk and support nucresiran launch in 2030.

HELIOS-B shows a 40% reduction in all-cause mortality and cardiovascular events over 48 months for AMVUTTRA.

TTR revenue guidance trimmed to $4.2–$4.5 billion (midpoint down about $200 million) as second-line demand growth stabilizes; total net product revenue guidance lowered to $4.7–$5.1 billion.

First-line patient starts account for roughly 80% of new initiations, signaling AMVUTTRA as a foundational therapy for newly diagnosed patients.

Cash balance improves to $3.3 billion as of June 30, 2026; non-GAAP operating income of $318 million, with higher non-GAAP R&D and SG&A due to AMVUTTRA launch and ongoing trials; prescriber base grows by over 1,700 since launch; BeOne partnership grants AMVUTTRA exclusivity for Mainland China and Macau pending marketing authorization; adherence exceeds 90%; multiple AI collaborations announced to aid diagnosis and market access.

Collaboration and royalty revenue guidance raised to $575–$625 million (midpoint up about $150 million) driven by Leqvio performance and Roche reimbursements.